A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 24 Dec 2017
At a glance
- Drugs SAR-439859 (Primary) ; Palbociclib
- Indications Adenocarcinoma; Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 11 Dec 2017 Planned End Date changed from 1 Aug 2020 to 17 Sep 2020.
- 11 Dec 2017 Planned primary completion date changed from 1 Aug 2020 to 17 Sep 2020.
- 25 Sep 2017 Status changed from not yet recruiting to recruiting.